RSV for Healthcare Providers

RSV Vaccination to Protect Adults

Respiratory syncytial virus (RSV) causes an estimated 110,000-180,000 hospitalizations among adults 50 and older in the United States each year. The Advisory Committee on Immunization Practices (ACIP) first recommended RSV vaccination for adults in June 2023.  According to RSVVaxView data, as of April 26, 2025, an estimated 47.5% of adults 75 years and older ever received an RSV vaccine and among adults 60-74 with a high-risk condition for RSV, 38% reported ever receiving an RSV vaccine. As a healthcare provider, your strong vaccination recommendation is a key factor in vaccine acceptance.

Adult RSV Vaccination Recommendation Timeline

Current Adult RSV Recommendations

A single dose of any FDA-licensed RSV vaccine for:

• All adults 75 and older
• Adults 50-74 at increased risk of severe RSV
  • Chronic lung or respiratory disease (COPD, asthma, interstitial lung disease, cystic fibrosis, emphysema)
  • Moderate or severe immune compromise
  • Chronic cardiovascular or liver disease
  • Chronic hematologic conditions
  • Diabetes complicated by chronic kidney disease, neuropathy, retinopathy, or other end-organ damage or requiring treatment with insulin or SGLT2 inhibitor
  • End-stage renal disease or dependence on hemodialysis or other renal replacement therapy
  • Severe obesity
  • Residing in a nursing home

For Healthcare Provider Education:

In this section, you will find healthcare provider resources from the American Lung Association and our partners pertaining to RSV disease and immunization.

For Patient Education:

Providing support to your patients can also mean providing science-based resources. In this section, you will find patient educational resources.

• RSV in Adults (webpage)
• RSV in Adults (animation)
• Lung HelpLine (professional call center)
• Patient & Caregiver Network (online support program)